Table 2.
Immunophenotyping analysis data on study population.
| HDs (n = 19) | COVID-19 subjects (n = 45) | p valuea | Severe (n = 14) | Non-severe (n = 31) | p valueb | |
|---|---|---|---|---|---|---|
| PMN cells (%) | 37.9 (31.7–43.6) | 33.2 (27.7–46.0) | ns | 29.5 (21.6–35.8) | 34.0 (29.0–54.0) | 0.032 |
| PMN/T ratio | 0.8 (0.7–1.0) | 1.3 (0.7–1.5) | 0.024 | 1.6 (1.3–2.3) | 0.7 (0.7–1.3) | <0.0001 |
| T cells (%) | 47 (40.1–53.2) | 29.0 (23.0–48.7) | 0.025 | 23.0 (17.4–25.9) | 42.2 (25.3–50.0) | 0.0004 |
| CD3 + CD8- cells (%) | 56 (52.5–59.2) | 47.8 (40.6–54.4) | <0.0001 | 40 (30.3–54.2) | 49.9 (45.1–54.6) | 0.049 |
| CD3 + CD8+ cells (%) | 25.6 (23.7–27.7) | 23.4 (20.0–31-3) | ns | 20.9 (18.1–24) | 26.4 (20.8–32.9) | 0.018 |
| CD3 + CD8-CD28-CD57+ cells (%) | 1.2 (0.6–2.8) | 3.7 (2.9–5.8) | ns | 3.9 (3.2–5.9) | 3.7 (2.8–5.7) | ns |
| CD3 + CD8 + CD28-CD57+ cells (%) | 10.4 (7.2–17.2) | 14.1 (6.9–20.8) | <0.0001 | 16.3 (10.2–22.6) | 11.6 (4.9–19.7) | ns |
| NK cells (%) | 14.7 (8.2–16.5) | 8.1 (5.7–17.7) | ns | 9.0 (5.9–18.5) | 8.1 (5.7–18.0) | ns |
| NK CD57+ cells (%) | 13.7 (5.0–20.5) | 25.9 (15.3–35.8) | 0.001 | 24.1 (12.9–35.3) | 26.5 (15.9–36.4) | ns |
| CD56bright cells (%) | 8.1 (6.1–13.2) | 5.8 (4.6–8.3) | 0.005 | 5.1 (3.2–7.8) | 6.7 (4.8–8.5) | ns |
| CD56dim cells (%) | 92.1 (87–94.3) | 93.4 (90.9–95.4) | 0.034 | 94.9 (92–96.4) | 92.7 (90.4–95.1) | ns |
| NKT cells (%) | 8.8 (5.8–12.1) | 3.8 (2.4–7.0) | 0.002 | 2.1 (0.8–4.1) | 4.7 (3.0–8.6) | 0.001 |
a
The nonparametric comparative Mann-Whitney test was used to compare medians between HDs and COVID-19 subjects
b
The nonparametric comparative Mann-Whitney test was used to compare medians between severe and non-severe groups. HDs: healthy donors, PMN/T: polymorphonuclear cell percentage/T cell percentage, ns: not significant.